The clinical significance of abnormal ejaculation by silodosin. Is it important?

Basit Öğe Kaydı
dc.authoridArda, Ersan/0000-0002-5430-6561
dc.authoridYazici, Cenk Murat/0000-0001-6140-5181
dc.authoridAKGUL, MURAT/0000-0001-6187-1940
dc.authoridSIPAL, TIMUCIN/0000-0003-3992-2013
dc.authorwosidakgül, murat/AGE-2468-2022
dc.authorwosidArda, Ersan/L-7357-2016
dc.authorwosidYazici, Cenk Murat/AAA-4330-2020
dc.contributor.authorAkgul, Murat
dc.contributor.authorYazici, Cenk
dc.contributor.authorSipal, Timucin
dc.contributor.authorArda, Ersan
dc.date.accessioned2024-06-12T10:50:15Z
dc.date.available2024-06-12T10:50:15Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractWe aimed to evaluate the effect of the abnormal ejaculation (AEj) on patients using silodosin in terms of drug cessation. We also analysed the possible factors that may affect the decisions of patients with AEj to proceed or change their medication. The patients (n = 118) treated with silodosin 8 mg daily were prospectively analysed. In order to evaluate the erectile function, ejaculatory function, depression and sexual satisfaction; IIEF, MSHQ-EjD, Beck's depression and Golombok-Rust questionnaires were given to patients respectively. Patients were re-evaluated at the 3rd month of their treatment. The rate of AEj was 52.5%. Nearly 42% of the patients with AEj desired to stop their medication whereas it was 7.1% at patients without AEj (p < .001). The pre-treatment International Prostate Symptom Score (IPSS) and the decrease in IPSS score were significantly lower in patients who demand to stop their treatment (p < .05). AEj was significantly higher in patients who wanted to stop their medication (p < .001). Even if they had an AEj, patients who were happy with the clinical efficacy of silodosin did not want to change their drug. In addition to this, pre-treatment ejaculatory status was an important indicator for patients to decide drug cessation due to AEj side effect of silodosin.en_US
dc.identifier.doi10.1111/and.14086
dc.identifier.issn0303-4569
dc.identifier.issn1439-0272
dc.identifier.issue7en_US
dc.identifier.pmid33951747en_US
dc.identifier.scopus2-s2.0-85105045449en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1111/and.14086
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17936
dc.identifier.volume53en_US
dc.identifier.wosWOS:000647260800001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofAndrologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAbnormal Ejaculationen_US
dc.subjectBenign Prostate Hyperplasiaen_US
dc.subjectSilodosinen_US
dc.subject? ? Blockersen_US
dc.titleThe clinical significance of abnormal ejaculation by silodosin. Is it important?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu